Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuChimeric antigen receptor T-cell therapy for solid tumorsMesothelin-Targeted CARs: Driving T Cells to Solid TumorsSynthetic biology approaches to engineer T cellsChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetChimeric antigen receptor therapy for cancerSmart CARs engineered for cancer immunotherapyLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesSynthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal.Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.Engineered T cells for cancer treatmentChimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survivalNew and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Human cancer growth and therapy in immunodeficient mouse models.Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsCo-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradientEngineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Mesothelin, a novel immunotherapy target for triple negative breast cancer.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity.Design and development of therapies using chimeric antigen receptor-expressing T cellsChimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivoVery Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Adoptive immunotherapy for cancer.
P2860
Q21131200-E0498C69-968A-49F4-B322-1D99D284813BQ26750908-03D22FF4-8D6C-4AD5-A3A4-242EB8A4DE66Q26778759-672825CA-1554-4715-8BCF-CF2A550F7DF4Q26798366-D6483CF1-9D34-48EB-A5A3-AAED4753498CQ26799357-BA2CE084-B8A7-4D96-98F4-53977D20A2E6Q27013599-6FA9DB9A-92EB-49FF-BB06-63687048A7F6Q28087236-F07B6BED-19C4-4D0A-B04A-2664DD827A08Q28395597-DF7A420C-098E-4A5A-B363-4C209F546C60Q30577136-9232A228-F98A-478C-BDB6-A1ABE722E3ADQ33555573-16A55182-97D9-4A31-9842-E1352F75F624Q33578792-78CAEDC4-0DD4-4427-849C-5C9E36A0B085Q34256494-B3722AEF-99E1-43F6-8851-3A1E0C671101Q34278435-E1080BE2-81C8-42A1-A157-C9636B5205D5Q34703865-0067272B-5E53-4985-B20C-4D0CBDA67940Q35042668-38E3607E-E836-4E96-8FA9-85504EFBE596Q35216278-4009D1E6-9E85-4A60-B4C6-E62078ECB2C9Q35545282-9D68475C-289C-4056-9DB7-36311EF4FCBEQ35597405-59297345-DA6C-4C29-B31F-A80AA5D8861AQ35612358-36735EAF-0CB5-49CA-B7A3-7653662412ECQ35711576-4C2D1E5E-686C-4DAB-AC58-41013FA3F987Q35980893-73F6F7EB-4B29-4148-B74C-CC88E326D48AQ36004154-426048A4-1878-4683-B2CA-CF1E4F136A5CQ36160526-2449DD14-2683-482C-9AC6-6157106BFAD7Q36470354-5B3E558D-5419-4F52-88CA-3BD1C624BF49Q36618810-2C6D733E-01FA-47EC-831F-AC12D4597926Q36811526-0CAFA4F2-528D-40DB-86AF-C107FE44C273Q36936632-0C6E39FD-9D18-4418-939E-F72A354F4F53Q36941051-D53D6858-F8EE-4D66-AB83-233738B939D1Q36963494-D7681592-38F7-4831-B6A5-E583CB242E8FQ37040202-F1D2BA7F-0EC7-449D-A5EB-58419A7CFDF0Q37090793-DB543830-1134-456E-94C2-B2B1D690DAFDQ37126006-E55AB379-70B6-4CA4-A885-6705E8E90C13Q37134884-60DAADAC-ABD6-4DFD-B6A2-895818099C42Q37257207-E53E3FF0-DD4F-44AB-895A-7EA024B3ED42Q37274068-D5E64A37-AC6B-4FC9-828B-C74444DDDC19Q37418289-5651EE2B-EC90-4B06-A2E6-BFE0ABDAF3BCQ37436837-8AC7CA8E-DA83-4815-AE23-C5DECC38EA66Q37492906-C4A001C4-E92B-466F-91AF-D4D9A15E55CFQ37728639-E0FF60DD-CCED-42C0-9DAB-5CF4D1BF0C62Q38170496-76C1E4F8-48E9-47A8-809B-7DB2F30D3E0C
P2860
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Expression of a functional CCR ...... ic chimeric antibody receptor.
@en
type
label
Expression of a functional CCR ...... ic chimeric antibody receptor.
@en
prefLabel
Expression of a functional CCR ...... ic chimeric antibody receptor.
@en
P2093
P2860
P1476
Expression of a functional CCR ...... ic chimeric antibody receptor.
@en
P2093
Carl H June
Carmine Carpenito
Daniel J Powell
Edmund K Moon
Jarrod Predina
Liang-Chuan S Wang
Steven M Albelda
Veena Kapoor
P2860
P304
P356
10.1158/1078-0432.CCR-11-0351
P407
P577
2011-05-24T00:00:00Z